Butyrylcholinesterase K Variant and Alzheimer’s Disease Risk: A Meta-Analysis

Zongcheng Wang 1,2
Yuren Jiang 1
Xi Wang 1
Yangsen Du 1
Dandan Xiao 1
Youchao Deng 1
Jinlian Wang 1

Corresponding Author: Yuren Jiang, e-mail: jiangyr@mail.csu.edu.cn

Source of support: The work was supported by the opening project of the key laboratory of comprehensive utilization of advantage plants resources in Hunan South, Hunan University of Science and Engineering (No. XNZW14C10); the construct program of the key discipline in Hunan Province (2012); and the aid program for science and technology innovative research teams in higher educational institutions of Hunan Province (No. 2012-318)

Background: Although many studies have estimated the association between the butyrylcholinesterase (BCHE) K variant and Alzheimer’s disease (AD) risk, the results are still controversial. We thus conducted this meta-analysis.

Material/Methods: We searched NCBI, Medline, Web of Science, and Embase databases to find all eligible studies. Odds ratios (ORs) with 95% confidence intervals (CIs) were used to assess the strength of the association.

Results: We found a significant association between BCHE K variant and AD risk (OR=1.20; 95% CI 1.03–1.39; \( P = 0.02 \)). In the stratified analysis by ethnicity, we observed a significant association between BCHE K variant and AD risk in Asians (OR=1.32; 95% CI 1.02–1.72; \( P = 0.04 \)). However, no significant association between BCHE K variant and AD risk in Caucasians was found (OR=1.14; 95% CI 0.95–1.37; \( P = 0.16 \)). When stratified by the age of AD onset, we found that late-onset AD (LOAD) was significantly associated with BCHE K variant (OR=1.44; 95% CI 1.05–1.97; \( P = 0.02 \)). No significant association between BCHE K variant and early-onset AD (EOAD) risk was observed (OR=1.16; 95% CI 0.89–1.51; \( P = 0.27 \)). Compared with non-APOE e4 and non-BCHE K carriers, no significant association between BCHE K variant and AD risk was found (OR=1.11; 95% CI 0.91–1.35; \( P = 0.30 \)). However, APOE e4 carriers showed increased AD risk in both non-BCHE K carriers (OR=2.81; 95% CI 1.75–4.51; \( P = 0.0001 \)) and BCHE K carriers (OR=3.31; 95% CI 1.82–6.02; \( P = 0.0001 \)).

Conclusions: The results of this meta-analysis indicate that BCHE K variant might be associated with AD risk.

MeSH Keywords: Alzheimer Disease • Butyrylcholinesterase • Genetics

Full-text PDF: http://www.medscimonit.com/abstract/index/idArt/892982
meta-analysis

Background

Alzheimer’s disease (AD) is one of the most common forms of dementia. The clinical manifestations of AD include loss of memory, and behavioral and cognitive disorders [1]. The survival time for patients with AD is generally 4 to 6 years after diagnosis. Thus, AD is a major public health concern. However, the etiology and pathogenesis of AD remain unclear. Recently, accumulating evidence shows that genetic factors might be involved in the development of AD [2].

Butyrylcholinesterase (BCHE) is a hydrolytic enzyme that can catalyze the hydrolysis of excess acetylcholine neurotransmission in the synaptic space. Darreh-Shori et al. suggested that low cerebrospinal fluid (CSF) levels of BCHE might predict extensive incorporation in neuritic plaques, greater central neurodegeneration, and increased neurotoxicity [3]. They also found that BCHE levels correlated with cerebral glucose metabolism, cerebral β-amyloid load, and CSF P-tau [4]. Diamant et al. reported an association of the BCHE-K variant with impaired interaction with the fibrillogenic beta-amyloid protein [5]. Shenhar-Tsarfaty also suggested that this variant could influence metabolic syndrome [6].

BCHE K variant is one of the most common polymorphism in the BCHE gene. This is an alanine-to-threonine substitution in the 539 amino acid position (Ala397Thr). This polymorphism is associated with a 30% reduction of serum BCHE activity [7]. Many studies have been conducted to evaluate the association between BCHE K variant and AD risk [8–32]. However, the results are controversial and inconsistent. Therefore, we performed a meta-analysis to assess the association between BCHE K variant and AD risk.

Material and Methods

Search for studies

We searched NCBI, Medline, Web of Science, and Embase databases to find all eligible studies. The last retrieval date was October 29, 2014. The following terms and keywords were used: (“Alzheimer’s disease” or “Alzheimer disease”) and (“Butyrylcholinesterase” or “BCHE”). All relevant studies were retrieved.

Inclusion and exclusion criteria

The inclusion criteria were as follows: (1) the study should be case-control or a cohort design; and (2) the study should focus on the association between BCHE K variant and AD risk. The exclusion criteria were as follows: (1) animal studies; (2) reviews or abstracts; and (3) duplications.

Results

Study characteristics

A total of 25 eligible case-control studies (3850 cases and 3947 controls) met the inclusion criteria [8–32]. Among these 25 case-control studies, 5 studies focused on Asians and 20 focused on Caucasians. The main characteristics of the included studies investigating the association of BCHE K variant and AD risk are presented in Table 1.

Association between BCHE K variant and AD risk

We found a significant association between BCHE K variant and AD risk (OR=1.20; 95% CI 1.03–1.39; P=0.02; Figure 1). In the stratified analysis by ethnicity (Table 2), we observed a significant association between BCHE K variant and AD risk in Asians (OR=1.32; 95% CI 1.02–1.72; P=0.04), but no significant association between BCHE K variant and AD risk in Caucasians was found (OR=1.14; 95% CI 0.95–1.37; P=0.16). When stratified by age at AD onset, we found that late-onset AD (LOAD) was significantly associated with BCHE K variant (OR=1.44; 95% CI 1.05–1.97; P=0.02). No significant association between BCHE K variant and early-onset AD (EOAD) risk was observed (OR=1.16; 95% CI 0.89–1.51; P=0.27).

Data extraction

According to the inclusion criteria, 2 investigators extracted the data independently. Any discrepancy was adjudicated by the third investigator. The following data was extracted from each study: first author, year, ethnicity, age and sex of patients, sample size, and genotyping results from BCHE and APOE genes.

Statistical analysis

The odds ratio (OR) and its 95% confidence interval (95% CI) were used to estimate the strength of the association between BCHE K variant and AD risk. A recessive model (KK vs. WW+WK) was applied. We estimated the heterogeneity by using the chi-square-based Q-test, which was considered significant at P<0.10. A fixed-effects model was used in the absence of heterogeneity; otherwise, a random-effects model was used. Subgroup analyses were performed based on ethnicity, APOE ε4 status, and the age at AD onset. We conducted sensitivity analysis by excluding every study individually and recalculating the OR and 95% CI. Potential publication bias was estimated using Egger’s linear regression test and the funnel plot. All statistical analyses were conducted using STATA software version 11.0 (Stata Corporation, College Station, TX). All P values were 2-sided, with a significance level of 0.05.
Compared with non-APOE ε4 and non-BCHE K carriers, no significant association between BCHE K variant and AD risk was found (OR=1.11; 95% CI 0.91–1.35; P=0.30). However, APOE ε4 carriers showed increased AD risk in both non-BCHE K carriers (OR=2.81; 95%CI 1.75–4.51; P=0.0001) and BCHE K carriers (OR=3.31; 95% CI 1.82–6.02; P=0.0001). Results are listed in Table 3.

Sensitivity analysis and publication bias

In the sensitivity analysis, the impact of each study on the pooled OR was checked by repeating the meta-analysis when omitting each study. This sensitivity analysis validated the stability of the results from this meta-analysis (Figure 2). The shape of funnel plots did not show any evidence of obvious asymmetry (Figure 3). Furthermore, the Egger's test result suggested that there was no significant publication bias (P=0.67).

### Table 1. Characteristics of the case-control studies included in meta-analysis.

| First author | Year | Ethnicity | Age | Sex | Case (n) | Control (n) | BCHE K allele frequency (%) | APOE ε4 allele frequency (%) |
|--------------|------|-----------|-----|-----|---------|------------|----------------------------|------------------------------|
|              |      |           |     |     |         |            | Case | Control | Case | Control |          |          |
| Lehmann      | 1997 | Caucasian | >65 | Mixed | 74     | 104        | 13    | 9       | 41   | 16       |
| Brindle      | 1998 | Caucasian | 75.4| Mixed | 138    | 165        | 20.3  | 18.8    | 31.4 | 14       |
| Crawford     | 1998 | Caucasian | 76.4| Mixed | 391    | 201        | 17.2  | 14.4    | 75   | 67.4     |
| Hiltunen     | 1998 | Caucasian | 73  | Mixed | 59     | 59         | 12    | 22      | 100  | 100      |
| Kehoe        | 1998 | Caucasian | NA  | Mixed | 181    | 262        | 21    | 22      | 56.5 | 28.1     |
| Singleton    | 1998 | Caucasian | 78.3| Mixed | 119    | 83         | 20    | 17      | 65.5 | 21.4     |
| Yamada       | 1998 | Asian     | 85.1| Mixed | 48     | 107        | 31.7  | 31.2    | NA   | NA       |
| Grubber      | 1999 | Caucasian | NA  | Mixed | 169    | 193        | 18.8  | 23      | 18   | 25.4     |
| Kim          | 1999 | Asian     | 73  | Mixed | 78     | 74         | 23    | 16      | 28   | 7        |
| Tilley       | 1999 | Caucasian | 81  | Mixed | 177    | 118        | 20    | 19      | 31   | 11       |
| Wiebusch     | 1999 | Caucasian | 78  | Mixed | 135    | 70         | 25    | 16      | 43   | 18       |
| Yamamoto     | 1999 | Asian     | 68.2| Mixed | 149    | 200        | 15.9  | 15.7    | NA   | NA       |
| Lee          | 2000 | Asian     | 69.1| Mixed | 89     | 101        | 13.5  | 12.3    | 24.2 | 6.9      |
| Mattila      | 2000 | Caucasian | >65 | Mixed | 80     | 67         | 21    | 15      | 13   | 11       |
| Mcllroy      | 2000 | Caucasian | 77.7| Mixed | 175    | 187        | 26.8  | 14.4    | 34.5 | 31.6     |
| Kim          | 2001 | Asian     | 71.7| Mixed | 164    | 293        | 11.7  | 10.1    | NA   | NA       |
| Prince       | 2001 | Caucasian | NA  | Mixed | 204    | 186        | 20.9  | 20.1    | NA   | NA       |
| Raygani      | 2004 | Caucasian | 75  | Mixed | 105    | 129        | 24.2  | 12      | 25.9 | 6.2      |
| Combarros    | 2005 | Caucasian | 75  | Mixed | 187    | 172        | 10    | 15      | 12   | 8        |
| Cook         | 2005 | Caucasian | NA  | Mixed | 212    | 316        | 27    | 20      | NA   | NA       |
| Deniz-Naranjo| 2007 | Caucasian | >60 | Mixed | 282    | 312        | 19.5  | 19.4    | 48.9 | 22.1     |
| Piccardi     | 2007 | Caucasian | 76.8| Mixed | 158    | 118        | 21    | 19      | 18.9 | 5.5      |
| Mateo        | 2008 | Caucasian | 71.3| Mixed | 231    | 221        | 12    | 10      | NA   | NA       |
| Bizzarro     | 2010 | Caucasian | 73.3| Mixed | 167    | 129        | 10.1  | 10.2    | NA   | NA       |
| Simão-Silva  | 2013 | Caucasian | 74.5| Mixed | 78     | 80         | 23    | 21      | NA   | NA       |

NA – not available.
Discussion

This meta-analysis with a total of 3850 cases and 3947 controls systematically evaluated the association between BCHE K variant and AD risk. Results from this meta-analysis suggested that BCHE K variant was significantly associated with AD risk. In the subgroup analysis by ethnicity, a significant association between BCHE K variant and AD risk in Asians was found, but this result was not found in Caucasians. This difference suggests that race might play a role in AD. Only 5 studies were included in our meta-analysis; thus, more studies with Asians are needed to confirm our results. In the stratified analysis by APOE e4 status, APOE e4 carriers, but not APOE e4 non-carriers with BCHE K variant, showed an increased AD risk. This result suggests that gene-gene interaction also plays an important role in the development of AD. More studies should be conducted to assess the interaction between other genes and BCHE K variant. When stratified by age at AD onset, we found that the risk of LOAD, but not EOAD, was significantly associated with BCHE K variant. This information indicates that age also has a critical role in AD development.

Table 2. Results from this meta-analysis.

| Study ID          | OR (95% CI)   | % weight |
|-------------------|---------------|----------|
| Lehmann (1997)    | 1.50 (0.83, 2.71) | 6.44     |
| Brindle (1998)    | 1.10 (0.74, 1.65) | 13.97    |
| Crawford (1998)   | 1.13 (0.81, 1.58) | 19.88    |
| Hiltunen (1998)   | 0.49 (0.04, 5.57) | 0.38     |
| Kehoe (1998)      | 0.48 (0.21, 1.12) | 3.17     |
| Singleton (1998)  | 2.12 (0.22, 20.75) | 0.44     |
| Yamada (1998)     | 4.20 (0.20, 88.21) | 0.24     |
| Gubbier (1999)    | 0.73 (0.30, 1.76) | 2.91     |
| Nii (1999)        | 1.57 (0.88, 2.81) | 6.68     |
| Tilley (1999)     | 1.81 (0.74, 4.99) | 1.25     |
| Wiebusch (1999)   | 4.35 (0.53, 35.48) | 0.51     |
| Yamamoto (1999)   | 1.27 (0.98, 1.60) | 18.47    |
| Lee (2000)        | 1.14 (0.62, 2.07) | 6.32     |
| Matilla (2000)    | 2.57 (0.26, 25.31) | 0.43     |
| McInroy (2000)    | 1.07 (0.21, 5.37) | 0.87     |
| Kim (2001)        | 1.80 (0.36, 9.03) | 0.87     |
| Prince (2001)     | 1.86 (0.63, 5.48) | 1.95     |
| Ragnani (2004)    | 9.14 (1.11, 75.54) | 0.51     |
| Combarros (2005)  | 0.78 (0.26, 2.37) | 1.84     |
| Cook (2005)       | 1.22 (0.55, 2.70) | 3.60     |
| Deniz-Naranjo (2007) | 0.97 (0.46, 2.02) | 4.18     |
| Piccardi (2007)   | 1.00 (0.34, 2.95) | 1.92     |
| Mateo (2008)      | 2.42 (0.47, 12.62) | 0.83     |
| Bizzarro (2010)   | 1.03 (0.23, 4.69) | 0.99     |
| Simiao-Silva (2013) | 1.58 (0.43, 5.84) | 1.33     |

EOAD – early-onset Alzheimer’s disease; LOAD – late-onset Alzheimer’s disease. * OR values refer to association between BCHE K variant and AD risk.

Table 3. APOE e4 and BCHE K variant interaction.

| APOE e4 | BCHE K | OR (95% CI) | % weight |
|---------|--------|-------------|----------|
| –       | –      | Reference   | –        |
| –       | +      | 1.11 (0.91–1.35) | 0.30 | 45 |
| +       | –      | 2.81 (1.75–4.51) | 0.0001 | 52 |
| +       | +      | 3.31 (1.82–6.02) | 0.0001 | 69 |

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License
Carson et al. found that BCHE activity was associated with the amyloid and the neuritic component in neuritic plaques [33]. Guillozet et al. also found that BCHE activity increased in the AD brain [34]. The activity of serum BCHE-K to hydrolyze butyrylthiocholine was found to be reduced by 30% relative to BCHE-U [7]. Thus, BCHE K variant might be associated with a decreased AD risk. However, Lopez et al. reported that BCHE K variant carriers were refractory to cholinesterase inhibitor therapy [35]. Additionally, Podoly et al. found that BCHE K variant had an elevated AD risk due to inefficient interference with amyloidogenic processes [36]. Furthermore, Ballard et al. found that BuCh E may play a role in the phosphorylation of tau, relevant to therapeutic inhibition of the enzyme [37]. Alkalay et al. found no association between BChE activity and amyloid loads in the AD brain [38]. Thus, the pathological role of BCHE K variant was still controversial. Our meta-analysis confirmed that this polymorphism might be associated with AD risk. More studies are needed to investigate the mechanism by which BCHE K variant could impact the risk of AD [39,40].

This meta-analysis had several limitations. First, results of this meta-analysis were based on unadjusted OR, because not all studies offered the adjusted ORs. Second, although the number of included studies was relatively large, the sample size and statistical power was still limited. Third, we only included the published studies; thus, publication bias and selection bias might exist. Forth, lack of sufficient eligible data on BCHE K variant and AD limited our further stratified analyses.

Conclusions

In conclusion, this study shows that BCHE K variant is associated with AD risk. More well-conducted studies with larger sample size are warranted to confirm our results.

Conflicts of interest

None.
References:

1. Finder VH: Alzheimer’s disease: a general introduction and pathomechanism. J Alzheimers Dis, 2010; 22(Suppl.3): 5–19

2. Kim DH, Yeo SH, Park JM et al: Genetic markers for diagnosis and pathogenesis of Alzheimer’s disease. Gene, 2014; 545(2): 185–93

3. Darreh-Shori T, Brimijoin S, Kadi R et al: Differential CSF butyrycholinesterase levels in Alzheimer’s disease patients with the ApoE epsilon4 allele, in relation to cognitive function and cerebral glucose metabolism. Neurobiol Dis, 2006; 24(2): 326–33

4. Darreh-Shori T, Forsberg A, Modiri N et al: Differential levels of apolipoprotein E and butyrylcholinesterase as strong association with pathological signs of Alzheimer’s disease in the brain in vivo. Neurobiol Aging, 2011; 32(12): 2320.e15–32

5. Diamant S, Podoly E, Friedler A et al: Butyrylcholinesterase attenuates amyloid fibril formation in vitro. Proc Natl Acad Sci USA, 2006; 103: 8626–33

6. Shenhar-Tsafary S, Berliner S, Bornstein NM, Soreq H: Cholinesterases as biomarkers for parasympathetic dysfunction and inflammation-related disease. J Mol Neurosci, 2014; 53: 298–305

7. Bartels CF, Jensen FS, Lockridge O et al: DNA mutation associated with the human butyrylcholinesterase K-variant and its linkage to the atypical variant mutation and other polymorphic sites. Am J Hum Genet, 1992; 50(5): 1086–1093

8. Lehmann DJ, Johnston C, Smith AD: Synergy between the genes for butyrylcholinesterase K variant and apolipoprotein E4 in late-onset confirmed Alzheimer’s disease. Hum Mol Genet, 1997; 6(11): 1933–36

9. Brindle N, Song Y, Rogaeva E et al: Analysis of the butyrylcholinesterase gene and nearby chromosome 3 markers in Alzheimer’s disease. Hum Mol Genet, 1998; 7(5): 933–35

10. Crawford F, Fallon D, Suo Z et al: The butyrylcholinesterase genes are neither independently nor synergistically associated with late-onset AD in clinic and community-based populations. Neurosci Lett, 1998; 249(2–3): 115–18

11. Hiltunen M, Mannnerma A, Heilsmi S et al: Butyrylcholinesterase K variant and apolipoprotein E4 genes do not act in synergy in Finnish late-onset Alzheimer’s disease patients. Neurosci Lett, 1998; 250(1): 69–71

12. Kehoe PG, Williams H, Holmans P et al: The butyrylcholinesterase K variant and susceptibility to Alzheimer’s disease. J Med Genet, 1998; 35(12): 1034–35

13. Singleton AB, Smith G, Gibson AM et al: No association between the K variant of the butyrylcholinesterase gene and pathologically confirmed Alzheimer’s disease. Hum Mol Genet, 1998; 7(5): 917–39

14. Yamada M, Sodeyama N, Itoh Y et al: Butyrylcholinesterase K variant and cerebral amyloid angiopathy. Stroke, 1998; 29(12): 2488–90

15. Grubber JM, Saunders AM, Crane-Gatherum AR et al: Analysis of association between Alzheimer disease and the K variant of butyrylcholinesterase (BCHE-K). Neurosci Lett, 1999; 269(2): 115–19

16. Ki CS, Na DL, Kim JW et al: No association between the genes for butyrylcholinesterase K variant and apolipoprotein E4 in late-onset Alzheimer’s disease. Am J Med Genet, 1999; 88(2): 113–15

17. Tilley L, Morgan K, Grainger J et al: Evaluation of polymorphisms in the pre-senilin-1 gene and the butyrylcholinesterase gene as risk factors in sporadic Alzheimer’s disease. Eur J Hum Genet, 1999; 7(6): 659–63

18. Wiebusch H, Poirier J, Sévigny P, Schappert K: Further evidence for a synergistic association between APOE epsilon4 and BCHE-K in confirmed Alzheimer’s disease. Hum Genet, 1999; 104(2): 158–63

19. Yamamoto Y, Yasuda M, Mori E, Maeda K: Failure to confirm a synergistic effect between the K-variant of the butyrylcholinesterase gene and the epsilon4 allele of the apolipoprotein gene in Japanese patients with Alzheimer’s disease. J Neurol Neurosurg Psychiatry, 1999; 67(1): 94–96

20. Lee DW, Liu HC, Liu TY et al: No association between butyrylcholinesterase K-variant and Alzheimer disease in Chinese. Am J Med Genet, 2000; 96(2): 167–69

21. Mattila KM, Rinne JO, Röyttä M et al: Dipeptidyl carboxypeptidase I (DCPI) and butyrylcholinesterase (BCHE) gene interactions with the apolipoprotein E epsilon4 allele as risk factors in Alzheimer’s disease and in Parkinson’s disease with coexisting Alzheimer pathology. J Med Genet, 2000; 37(10): 766–70

22. McIroy SP, Crawford VL, Dyan KB et al: Butyrylcholinesterase K variant is genetically associated with late onset Alzheimer’s disease in Northern Ireland. J Med Genet, 2000; 37(3): 182–85

23. Kim KW, Jhoo JH, Lee JH et al: Neither the butyrylcholinesterase K variant nor transferrin C2 variant confers a risk for Alzheimer’s disease in Koreans. J Neurol Transm, 2001; 108(10): 1159–66

24. Prince JA, Feuk L, Sawyer SL et al: Lack of replication of association findings in complex disease: an analysis of 15 polymorphisms in prior candidate genes for sporadic Alzheimer’s disease. Eur J Hum Genet, 2001; 9(6): 437–44

25. Raygani AV, Zahrai M, Soltanzadeh A et al: Analysis of association between butyrylcholinesterase K variant and apolipoprotein E genotypes in Alzheimer’s disease. Neurosci Lett, 2004; 371(2–3): 142–46

26. Combarros O, Blanco JA, Infante J et al: Interaction between CYP19 aromatase and butyrylcholinesterase genes increases Alzheimer’s disease risk. Dement Geriatr Cogn Disord, 2005; 20(2–3): 153–57

27. Cook LJ, Ho LW, Wang L et al: Candidate gene association studies of genes involved in neuronal cholinergic transmission in Alzheimer disease suggests choline acetyltransferase as a candidate deserving further study. Am J Med Genet B Neuropsychiatr Genet, 2005; 132B(1): 5–8

28. Déniz-Naranjo MC, Muñoz-Fernández C, Alegany-Rodríguez MJ et al: Butyrylcholinesterase, ApoE and Alzheimer’s disease in a population from the Canary Islands (Spain). Neurosci Lett, 2007; 427(1): 34–38

29. Piccardi M, Congiu D, Squassina A et al: Alzheimer’s disease: case-control association study of polymorphisms in ABC2, CHAT, and BCHE genes in a Sardinian sample. Am J Med Genet B Neuropsychiatr Genet, 2007; 144B(7): 895–99

30. Mateo I, Llorca J, Infante J et al: Gene-gene interaction between 14-3-3 zeta and butyrylcholinesterase modulates Alzheimer’s disease risk. Eur J Neurol, 2008; 15(3): 219–22

31. Bizzaro A, Guggilemi V, Lamastro R et al: Butyrylcholinesterase K variant is decreased in Alzheimer’s disease not in fronto-temporal dementia. J Neurol Transm, 2010; 117(3): 377–83

32. Simão-Silva DP, Bertolucci PH, de Labio RW et al: Association analysis between K and -116A variants of butyrylcholinesterase and Alzheimer’s disease in a Brazilian population. Chem Biol Interact, 2013; 203(1): 358–60

33. Carson KA, Geula C, Mesulam MM: Electron microscopic localization of cholinesterase activity in Alzheimer brain tissue. Brain Res, 1991; 540(1–2): 204–8

34. Guillotol AL, Smiley IF, Mash DC, Mesulam MM: Butyrylcholinesterase in the life cycle of amyloid plaques. Ann Neurol, 1997; 42(6): 909–18

35. Lopez OL, Becker JT, Wisniewski S et al: Cholinesterase inhibitor treatment alters the natural history of Alzheimer’s disease. J Neurol Neurosurg Psychiatry, 2002; 72(3): 310–14

36. Podoly E, Shaloe DE, Shenhar-Tsafary S et al: The butyrylcholinesterase K variant confers structurally derived risks for Alzheimer pathology. J Biol Chem, 2009; 284(25): 17170–79

37. Ballard C, Morris C, Kalaria R et al: The k variant of the butyrylcholinesterase gene is associated with reduced phosphorylation of tau in dementia patients. Dement Geriatr Cogn Disord, 2005; 19(5–6): 357–60

38. Alkalay A, Rabinovici GD, Zimmerman G et al: Plasma acetylcholinesterase activity correlates with intracerebral β-amyloid load. Curr Alzheimer Res, 2013; 10(1): 48–56

39. Zhang T, Jia Y: Meta-analysis of Ubiquilin1 gene polymorphism and Alzheimer’s disease risk. Med Sci Monit, 2013; 21: 2250–55

40. Zimny A, Bladowska I, Neska M et al: Quantitative MR evaluation of atrophy, as well as perfusion and diffusion alterations within hippocampi in patients with Alzheimer’s disease and mild cognitive impairment. Med Sci Monit, 2013; 19: 86–94